Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD2811 Nanoparticles as Monotherapy or in Combination in Acute Myeloid Leukemia Participants.

Trial Identifier: D6130C00003
Sponsor: AstraZeneca
NCTID:: NCT03217838
Start Date: July 2017
Primary Completion Date: March 2021
Study Completion Date: March 2021
Condition: Leukemia

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
English version
English Translation

Trial Locations

Country Location
AU Melbourne, AU, 3004
US, CO Denver, CO, US, 80218
US, FL Sarasota, FL, US, 34232
US, MI Detroit, MI, US, 48201
US, NC Charlotte, NC, US, 28204
US, OH Canton, OH, US, 44718
US, OK Oklahoma City, OK, US, 73104
US, TN Nashville, TN, US, 37203
US, TX Dallas, TX, US, 75246
US, TX Houston, TX, US, 77030
US, TX San Antonio, TX, US, 78229
US, WI Milwaukee, WI, US, 53226